Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes

Ajay Madan, Richard A. Graham, Kathleen M. Carroll, Daniel R. Mudra, L. Alayne Burton, Linda A. Krueger, April D. Downey, Maciej Czerwinski, Jameson Forster, Maria D. Ribadeneira, Liang-Shang Gan, Edward L. LeCluyse, Karl Zech, Philmore Robertson Jr., Patrick Koch, Lida Antonian, Greg Wagner, Li Yu and Andrew Parkinson
Drug Metabolism and Disposition April 2003, 31 (4) 421-431; DOI: https://doi.org/10.1124/dmd.31.4.421
Ajay Madan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard A. Graham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Carroll
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel R. Mudra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Alayne Burton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda A. Krueger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
April D. Downey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maciej Czerwinski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jameson Forster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria D. Ribadeneira
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liang-Shang Gan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward L. LeCluyse
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl Zech
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philmore Robertson Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Koch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lida Antonian
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg Wagner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Yu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Parkinson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Cultured human hepatocytes are a valuable in vitro system for evaluating new molecular entities as inducers of cytochrome P450 (P450) enzymes. The present study summarizes data obtained from 62 preparations of cultured human hepatocytes that were treated with vehicles (saline or dimethylsulfoxide, 0.1%), β-naphthoflavone (33 μM), phenobarbital (100 or 250 μM), isoniazid (100 μM) and/or rifampin (20 or 50 μM), and examined for the expression of P450 enzymes based on microsomal activity toward marker substrates, or in the case of CYP2C8, the level of immunoreactive protein. The results show that CYP1A2 activity was markedly induced by β-naphthoflavone (on average 13-fold, n = 28 preparations), and weakly induced by phenobarbital (1.9-fold, n = 25) and rifampin (2.3-fold, n = 22); CYP2A6 activity tended to be increased with phenobarbital (n = 7) and rifampin (n = 3) treatments, but the effects were not statistically significant; CYP2B6 was induced by phenobarbital (6.5-fold, n = 13) and rifampin (13-fold,n = 14); CYP2C8 was induced by phenobarbital (4.0-fold, n = 4) and rifampin (5.2-fold,n = 4); CYP2C9 was induced by phenobarbital (1.8-fold, n = 14) and rifampin (3.5-fold,n = 10); CYP2C19 was markedly induced by rifampin (37-fold, n = 10), but relatively modestly by phenobarbital (7-fold, n = 9); CYP2D6 was not significantly induced by phenobarbital (n = 5) or rifampin (n = 5); CYP2E1 was induced by phenobarbital (1.7-fold, n = 5), rifampin (2.2-fold, n = 5), and isoniazid (2.3-fold,n = 5); and, CYP3A4 was induced by phenobarbital (3.3-fold, n = 42) and rifampin (10-fold,n = 61), but not by β-naphthoflavone. Based on these observations, we generalize that β-naphthoflavone induces CYP1A2 and isoniazid induces CYP2E1, whereas rifampin and, to a lesser extent phenobarbital, tend to significantly and consistently induce enzymes of the CYP2A, CYP2B, CYP2C, CYP2E, and CYP3A subfamilies but not the 2D subfamily.

Footnotes

  • ↵1 Neurocrine Biosciences, 10555 Science Center Dr, San Diego, CA.

  • ↵2 School of Pharmacy, Division of Pharmaceutics, University of North Carolina-Chapel Hill, NC.

  • ↵3 Astra Zeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE.

  • ↵4 Millenium Pharmaceuticals, 270 Albany St., Cambridge, MA.

  • A preliminary account of this work was presented at the International Society for the Study of Xenobiotics (ISSX) meeting, 2000 June 11–16, St. Andrews, Scotland.

  • Abbreviations used are::
    NME
    new molecular entity (also known as NCE, new chemical entity)
    P450
    cytochrome P450
    BCA
    bicinchoninic acid
    ANOVA
    analysis of varience
    EROD
    7-ethoxyresorufin O-dealkylase
    7-EFCOD
    7-ethoxytrifluoromethylcoumarin O-dealkylase
    DMSO
    dimethylsulfoxide
    CAR
    constitutive androstane receptor
    PXR
    pregnane X receptor
    • Received September 24, 2002.
    • Accepted December 20, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 31 (4)
Drug Metabolism and Disposition
Vol. 31, Issue 4
1 Apr 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes

Ajay Madan, Richard A. Graham, Kathleen M. Carroll, Daniel R. Mudra, L. Alayne Burton, Linda A. Krueger, April D. Downey, Maciej Czerwinski, Jameson Forster, Maria D. Ribadeneira, Liang-Shang Gan, Edward L. LeCluyse, Karl Zech, Philmore Robertson, Patrick Koch, Lida Antonian, Greg Wagner, Li Yu and Andrew Parkinson
Drug Metabolism and Disposition April 1, 2003, 31 (4) 421-431; DOI: https://doi.org/10.1124/dmd.31.4.421

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes

Ajay Madan, Richard A. Graham, Kathleen M. Carroll, Daniel R. Mudra, L. Alayne Burton, Linda A. Krueger, April D. Downey, Maciej Czerwinski, Jameson Forster, Maria D. Ribadeneira, Liang-Shang Gan, Edward L. LeCluyse, Karl Zech, Philmore Robertson, Patrick Koch, Lida Antonian, Greg Wagner, Li Yu and Andrew Parkinson
Drug Metabolism and Disposition April 1, 2003, 31 (4) 421-431; DOI: https://doi.org/10.1124/dmd.31.4.421
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics